Make an Inquiry
Accelerating Primary Sclerosing Cholangitis Drug Development

Primary sclerosing cholangitis (PSC) presents a significant therapeutic challenge due to its complex pathogenesis and lack of effective treatment options. Protheragen stands at the forefront of PSC drug development, offering specialized expertise and resources tailored to address this unmet medical need. Protheragen delivers comprehensive preclinical solutions spanning target validation, lead optimization, pharmacology, and IND-enabling studies, ensuring a seamless transition from discovery to clinical readiness. Our scientific team brings deep experience in hepatology and immunology, supported by advanced assay platforms and state-of-the-art in vivo models specific to PSC. With a rigorous approach to regulatory compliance and data integrity, Protheragen aligns every project with current global standards, facilitating efficient and reliable progression through the preclinical pipeline. Driven by innovation and scientific rigor, Protheragen is committed to accelerating the development of transformative therapeutics for PSC, empowering partners to bring new hope to patients affected by this challenging disease.

What is Primary Sclerosing CholangitisTargets for Primary Sclerosing CholangitisDrug Discovery and Development ServicesWhy Choose Us

What is Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis (PSC) is a chronic, progressive liver disease characterized by inflammation, fibrosis, and stricturing of the intrahepatic and/or extrahepatic bile ducts. While the exact cause remains unclear, PSC is believed to result from a combination of genetic susceptibility, abnormal immune responses, and environmental factors. The disease is strongly associated with inflammatory bowel disease, particularly ulcerative colitis, suggesting an immunologic link. Pathologically, PSC is marked by concentric ("onion-skin") periductal fibrosis and obliterative cholangitis, which over time lead to biliary cirrhosis, portal hypertension, and an increased risk of hepatobiliary malignancies such as cholangiocarcinoma. Clinically, PSC often presents with symptoms of cholestasis, including pruritus, fatigue, and jaundice, though some patients may be asymptomatic at diagnosis. Laboratory findings typically reveal elevated cholestatic liver enzymes. Diagnosis is primarily based on magnetic resonance cholangiopancreatography (MRCP), which shows multifocal strictures and beading of the bile ducts, supported by exclusion of secondary causes. Liver biopsy may be used in certain cases, such as suspected small duct PSC or overlap syndromes. There is currently no curative medical therapy; management focuses on symptom control, surveillance for complications, and, in advanced disease, liver transplantation, which remains the only definitive treatment.

Learn More

Targets for Primary Sclerosing Cholangitis

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
peroxisome proliferator activated receptor delta PPARD
peroxisome proliferator activated receptor alpha PPARA
C-C motif chemokine ligand 24 CCL24
C-C motif chemokine receptor 2 CCR2
nuclear receptor subfamily 1 group I member 2 NR1I2
nuclear receptor subfamily 1 group H member 4 NR1H4
C-C motif chemokine receptor 5 CCR5
NFE2 like bZIP transcription factor 2 NFE2L2
solute carrier family 10 member 2 SLC10A2
poly(ADP-ribose) polymerase 1 PARP1

Primary sclerosing cholangitis (PSC) involves a complex interplay of molecular pathways driving cholestasis, inflammation, and fibrosis. Key therapeutic targets include ATP-binding cassette transporters ABCB11 (BSEP) and ABCB4 (MDR3), which are crucial for the export of bile acids and phospholipids from hepatocytes. Dysfunction in these transporters leads to toxic bile accumulation and bile duct injury. Nuclear receptors such as FXR (NR1H4) and PXR (NR1I2) regulate bile acid synthesis, conjugation, and transport, modulating both hepatobiliary homeostasis and inflammatory signaling. In addition, chemokine receptors CCR2 and CCR5, along with their ligand CCL24, mediate immune cell recruitment to the biliary tree, sustaining chronic inflammation. Fibrogenic responses are driven by targets like PDGFRB and THBS1, which stimulate hepatic stellate cell activation and extracellular matrix deposition, promoting progression to cirrhosis. The therapeutic potential of these targets is reflected in ongoing drug development efforts. FXR agonists (such as obeticholic acid) and PXR modulators aim to restore bile acid homeostasis and reduce hepatotoxicity. CCR2 and CCR5 antagonists, including cenicriviroc and maraviroc, are under clinical evaluation for their ability to attenuate hepatic inflammation and fibrosis. Anti-fibrotic strategies targeting PDGFRB and THBS1 are also being explored in preclinical and early clinical studies. These targets not only offer avenues for novel therapies but may serve as biomarkers for disease activity, progression, and therapeutic response, supporting precision medicine approaches in PSC.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Primary Sclerosing Cholangitis (PSC) drug discovery by providing robust, sensitive cellular and molecular assays targeting key PSC pathways. We offer chemiluminescent, gene reporter, HTRF, luciferase, RNA, peptide recruitment, and taurocholate uptake assays to assess compound effects on bile acid transporters, nuclear receptors, and inflammatory mediators. Quantitative parameters such as EC-50, IC-50, MEC, and MIC enable precise efficacy profiling and mechanism-of-action insights. This comprehensive platform empowers high-confidence decision-making, supporting candidate selection and optimization for PSC therapeutics in early-stage drug development.

Atp Binding Cassette Subfamily B Member 11 Atp Binding Cassette Subfamily B Member 4
C-C Motif Chemokine Receptor 2 C-C Motif Chemokine Receptor 5
Nuclear Receptor Subfamily 1 Group H Member 4 Peroxisome Proliferator Activated Receptor Alpha
Peroxisome Proliferator Activated Receptor Delta Platelet Derived Growth Factor Receptor Beta
Solute Carrier Family 10 Member 2

Learn More

Why Choose Us

Choosing Protheragen as your partner in the development of new therapeutics for Primary sclerosing cholangitis means entrusting your project to a team with specialized expertise in this challenging field. At Protheragen, our scientists and clinicians possess deep knowledge and years of hands-on experience in Primary sclerosing cholangitis research and drug development, ensuring that every project benefits from the latest scientific advances and therapeutic strategies. Our professional teams utilize advanced technology platforms, allowing us to deliver innovative and efficient solutions tailored to the unique requirements of each program. Protheragen has established a strong track record of reliability in preclinical drug development services, consistently meeting project milestones and exceeding client expectations. We maintain the highest quality standards and adhere strictly to regulatory compliance, ensuring that all studies are conducted with rigor and transparency. Above all, Protheragen is deeply committed to advancing new therapies for Primary sclerosing cholangitis, working closely with our partners to bring hope and better outcomes to patients worldwide. Your trust in Protheragen is a step toward meaningful progress in the fight against this complex disease.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Primary Sclerosing Cholangitis (PSC)?

A: One of the key challenges in PSC preclinical research is the lack of robust and predictive animal models that accurately recapitulate the human disease pathology. PSC is a complex, multifactorial disease with an unclear etiology, making it difficult to model its progression and response to therapies in vivo. Additionally, the slow progression of PSC and its heterogeneity in patient populations further complicate translational research. Our company addresses these challenges by utilizing a combination of in vitro systems, including human-derived cholangiocyte cultures, and the latest genetically engineered animal models, ensuring more relevant and translatable data.

Q: What are the primary regulatory considerations for preclinical drug development targeting PSC?

A: Regulatory agencies such as the FDA and EMA require comprehensive preclinical data demonstrating safety, pharmacokinetics, and proof-of-concept efficacy before proceeding to clinical trials for PSC. Given the rarity and complexity of PSC, it is essential to engage with regulators early to align on study design, endpoints, and model selection. Our team is experienced in preparing regulatory documentation, including IND-enabling studies, and can assist with pre-IND meetings to ensure that our clients’ preclinical programs meet the expectations for orphan drug indications like PSC.

Q: What are the key technical aspects to consider in preclinical research for PSC drug development?

A: Technical considerations include the selection of appropriate in vitro and in vivo models, the development of reliable biomarkers for disease progression and drug efficacy, and the need for sensitive assays to measure bile duct injury and fibrosis. Our company offers a suite of technical solutions, including advanced imaging, histopathology, and molecular analyses tailored to cholangiopathies. We also employ state-of-the-art omics technologies to elucidate drug mechanisms and identify predictive biomarkers.

Q: What are the typical timeline and cost considerations for the preclinical phase of PSC drug development?

A: Preclinical development timelines for PSC can range from 18 to 36 months, depending on the complexity of the drug candidate and the need for specialized models or assays. Costs are influenced by the rarity of the disease, the need for custom model development, and comprehensive safety and efficacy studies, often ranging from $2 million to $5 million for a full IND-enabling package. Our company provides detailed project planning and cost transparency, leveraging our expertise to optimize timelines and budgets while ensuring scientific rigor.

Q: What are the critical success factors in preclinical drug development for PSC?

A: Success in PSC preclinical drug development hinges on early and accurate disease modeling, the identification of relevant biomarkers, and robust demonstration of drug efficacy and safety. Close collaboration with regulatory agencies and leveraging multidisciplinary expertise are also essential. At our company, we prioritize scientific excellence, regulatory compliance, and client communication, ensuring that each project is positioned for a smooth transition to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.